AcelRx Pharmaceuticals was founded in 2005 and is headquartered in Redwood City, US

AcelRx Pharmaceuticals has an office in Redwood City

Redwood City, US (HQ)

351 Galveston Dr

AcelRx Pharmaceuticals's revenue was reported to be $3.1 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 3.1 m |

## Gross profit (Q1, 2017) | (1 m) |

## Gross profit margin (Q1, 2017), % | (33%) |

## Net income (Q1, 2017) | (15.6 m) |

## EBIT (Q1, 2017) | (12.1 m) |

## Market capitalization (21-Jul-2017) | 142.8 m |

## Cash (31-Mar-2017) | 72.3 m |

AcelRx Pharmaceuticals's current market capitalization is $142.8 m.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 29.5 m | 5.2 m | 19.3 m | 17.4 m |

## Revenue growth, % | (82%) | 269% | (10%) | |

## Cost of goods sold | 1.8 m | 12.3 m | ||

## Gross profit | 17.5 m | 5 m | ||

## Gross profit Margin, % | 91% | 29% | ||

## R&D expense | 21.4 m | |||

## General and administrative expense | 15.6 m | |||

## Operating expense total | 36.2 m | 42.9 m | 39.2 m | 49.3 m |

## EBIT | (6.7 m) | (37.6 m) | (20 m) | (32 m) |

## EBIT margin, % | (23%) | (722%) | (104%) | (184%) |

## Interest expense | 1.5 m | 2.6 m | 3 m | 2.8 m |

## Pre tax profit | (33.4 m) | (23.6 m) | (43.2 m) | |

## Income tax expense | 760 k | (34 k) | ||

## Net Income | (23.4 m) | (33.4 m) | (24.4 m) | (43.2 m) |

USD | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|

## Revenue | 15.4 m | 3 m | 4.5 m | 3.4 m | 3.1 m |

## Cost of goods sold | 3.6 m | 3 m | 2.6 m | 4.1 m | |

## Gross profit | (574 k) | 1.6 m | 787 k | (1 m) | |

## Gross profit Margin, % | (19%) | 34% | 23% | (33%) | |

## R&D expense | 5.4 m | 4.2 m | 6.3 m | 4.6 m | 6.9 m |

## General and administrative expense | 2.9 m | 3.8 m | 3.6 m | 4.1 m | 4.1 m |

## Operating expense total | 8.3 m | 7.9 m | 9.9 m | 8.8 m | 11.1 m |

## EBIT | 7.1 m | (8.5 m) | (8.3 m) | (8 m) | (12.1 m) |

## EBIT margin, % | 46% | (282%) | (184%) | (237%) | (388%) |

## Interest expense | (713 k) | (680 k) | (687 k) | (702 k) | (774 k) |

## Pre tax profit | (11 m) | (11.1 m) | (15.6 m) | ||

## Income tax expense | (772 k) | (2 k) | |||

## Net Income | 5.1 m | (11 m) | (11.1 m) | (11.4 m) | (15.6 m) |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 88.4 m | 60 m | 107.9 m | 80.3 m |

## Accounts Receivable | 3.3 m | 5.8 m | ||

## Inventories | 897 k | 948 k | 466 k | 2.2 m |

## Current Assets | 104.6 m | 76.3 m | 118.9 m | 89.1 m |

## PP&E | 5.2 m | 9.8 m | 8.6 m | 10.7 m |

## Total Assets | 110 m | 86.4 m | 127.8 m | 100 m |

## Accounts Payable | 2.3 m | 2.4 m | 1.6 m | 1.6 m |

## Total Debt | 14.4 m | 24.9 m | 20.9 m | 18.6 m |

## Current Liabilities | 6.9 m | 13.7 m | 12.8 m | 10.2 m |

## Total Liabilities | 105.3 m | |||

## Additional Paid-in Capital | 218.6 m | 225.4 m | 236.3 m | 241 m |

## Retained Earnings | (145.5 m) | (178.8 m) | (203.2 m) | (246.4 m) |

## Total Equity | 73.2 m | 46.7 m | 33.1 m | (5.3 m) |

## Debt to Equity Ratio | 0.2 x | 0.5 x | 0.6 x | -3.5 x |

## Debt to Assets Ratio | 0.1 x | 0.3 x | 0.2 x | 0.2 x |

## Financial Leverage | 1.5 x | 1.9 x | 3.9 x | -18.7 x |

USD | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|

## Cash | 95 m | 105.4 m | 97.8 m | 92.5 m | 72.3 m |

## Accounts Receivable | 17.4 m | 3.2 m | 4.2 m | 2 m | 2.7 m |

## Inventories | 910 k | 1.3 m | 1.4 m | 1.9 m | |

## Current Assets | 122.6 m | 112.8 m | 105.6 m | 96.9 m | 78 m |

## PP&E | 8.7 m | 8.2 m | 7.8 m | 8.8 m | 10.2 m |

## Total Assets | 131.6 m | 121.2 m | 113.6 m | 106 m | 88.4 m |

## Accounts Payable | 1.7 m | 3.6 m | 2.9 m | 1.4 m | 1.7 m |

## Current Liabilities | 7.9 m | 16.8 m | 21 m | 15.5 m | 12.8 m |

## Additional Paid-in Capital | 232.6 m | 237.6 m | 238.7 m | 239.9 m | 242.2 m |

## Retained Earnings | (192.7 m) | (214.2 m) | (225.3 m) | (236.7 m) | (261.9 m) |

## Total Equity | 40 m | 23.4 m | 13.5 m | 3.3 m | |

## Financial Leverage | 3.3 x | 5.2 x | 8.4 x | 32.4 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (23.4 m) | (33.4 m) | (24.4 m) | (43.2 m) |

## Depreciation and Amortization | 593 k | 866 k | 2 m | 2.1 m |

## Accounts Receivable | (3.3 m) | (2.5 m) | ||

## Inventories | (466 k) | (1.7 m) | ||

## Accounts Payable | 106 k | 90 k | (786 k) | (437 k) |

## Cash From Operating Activities | (487 k) | (34.5 m) | (20 m) | (29.4 m) |

## Purchases of PP&E | (3.3 m) | (5.5 m) | (1.5 m) | (3.7 m) |

## Cash From Investing Activities | (6.9 m) | (5.8 m) | 8.2 m | 1.8 m |

## Cash From Financing Activities | 47.9 m | 11.9 m | 59.6 m | (26 k) |

## Interest Paid | 1.1 m | 1.8 m | 2.1 m | 1.9 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|

## Net Income | 5.1 m | (11 m) | (11.1 m) | (11.4 m) | (15.6 m) | |||

## Accounts Receivable | 17.4 m | 3.2 m | 4.2 m | 2 m | 2.7 m | |||

## Inventories | 910 k | 1.3 m | 1.4 m | 1.9 m | ||||

## Accounts Payable | 2.8 m | 2.9 m | 1.6 m | 1.7 m | 3.6 m | 2.9 m | 1.4 m | 1.7 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 79.7 k |